Evidence at a glance
Human clinical evidence 2 of 3 (moderate), preclinical evidence 3 of 3 (substantial).
My read of the published evidence, not a rating of whether it works. Preclinical findings cannot establish human benefit.
What is SS-31?
SS-31, or elamipretide if you prefer its drug name, is a small synthetic peptide of just four amino acids. Hazel Szeto and Peter Schiller designed it in the early 2000s, and the SS is simply their initials. Unlike most peptides in the longevity conversation, this one was built in an academic lab with a specific engineering goal: get a molecule to accumulate inside mitochondria, the structures that generate most of a cell's energy.
That goal turned into a real drug-development program. Stealth BioTherapeutics has run elamipretide through formal clinical trials for over a decade, in conditions ranging from rare genetic mitochondrial diseases to heart failure and an advanced form of macular degeneration. So SS-31 sits in an odd spot. It circulates in grey-market 'research peptide' catalogs while simultaneously being a serious investigational medicine with a regulatory paper trail.
Why researchers are interested
Elamipretide's trick is selectivity. It concentrates in the inner mitochondrial membrane, by some estimates thousands-fold over its concentration elsewhere, because it binds cardiolipin, a phospholipid found almost exclusively there. Cardiolipin helps organize the protein complexes of the electron transport chain, the assembly line that turns food into ATP. When cardiolipin is damaged or oxidized, as happens in aging and in many diseases, that assembly line gets sloppy: less energy, more reactive oxygen species.
By stabilizing cardiolipin and the membrane structures around it, elamipretide is thought to improve the efficiency of energy production and reduce oxidative leak at the source, rather than mopping up free radicals downstream the way a generic antioxidant would. Since mitochondrial decline is one of the recognized hallmarks of aging, a molecule that targets the machinery directly is inherently interesting to longevity researchers. Which is exactly why it escaped the clinic and landed in enthusiast forums.
Regulatory status
Elamipretide is an investigational drug. It has been studied under regulatory oversight in the US and elsewhere, including in Barth syndrome, a rare genetic mitochondrial disease where it has received close FDA attention. As of this writing it is not an authorized medicine in Canada, and no elamipretide product has been approved by Health Canada for any indication.
The vials sold online as 'SS-31' are not the clinical-trial material. They are unauthorized products from unregulated suppliers, and their identity, purity, and sterility are unverified.
What human research shows
Elamipretide has something most forum-famous peptides lack entirely: randomized, placebo-controlled human trials. The results have been genuinely mixed. In Barth syndrome, the TAZPOWER trial and its open-label extension produced signals of improved function that were compelling enough to keep the regulatory process alive for years. In primary mitochondrial myopathy, a large phase 3 trial (MMPOWER-3) missed its primary endpoints. Sobering, for a mechanism that looked this strong in earlier studies.
Trials in heart failure and in dry age-related macular degeneration have likewise produced a mix of encouraging secondary findings and failed primary endpoints. So the summary is this: a real drug candidate with real human data, and that data says the benefits, where they exist, are condition-specific and harder to demonstrate than the mechanism suggests. None of the trials studied healthy people seeking better energy or slower aging.
What early research shows
The preclinical literature is extensive and, frankly, impressive. In aged mice, elamipretide has improved mitochondrial energetics in heart and skeletal muscle within an hour of administration in some experiments. Animal models of heart failure, kidney injury, and muscle atrophy have repeatedly shown protective effects.
But the gap between MMPOWER-3's animal-model rationale and its human result is a case study in why preclinical data cannot establish human benefit. Mice are not small humans, and mitochondrial biology is notoriously context-dependent. The cell and animal work explains why elamipretide is worth trialing. It does not tell you what it will do in a person.
What it's being studied for
Elamipretide's clinical program has focused on conditions where mitochondrial dysfunction is central, while academic groups probe the aging angle.
- Researchers are investigating whether elamipretide improves cardiac function in Barth syndrome
- Researchers are studying its effects on skeletal muscle energetics in older adults
- Researchers are testing whether it slows progression of certain retinal diseases
- Researchers are examining its effects in heart failure with impaired energy metabolism
- Researchers are exploring whether cardiolipin stabilization alters markers of mitochondrial aging
What remains uncertain
Long-term safety in healthy people is unstudied. Every trial enrolled patients with specific diseases, under medical monitoring. Whether the doses, durations, and delivery methods used in trials translate to any benefit outside those diseases is unknown, and there is no established use in healthy adults, full stop.
For anyone eyeing grey-market vials, add a more basic uncertainty: whether the powder is elamipretide at all. Unregulated peptide products have repeatedly been found to contain the wrong substance, the wrong amount, or bacterial endotoxins. With an injectable, that is not a trivial risk.
What people report
Anecdotes from self-experimenters cluster around subjective energy. People report feeling less fatigued, recovering faster, or noticing nothing at all. These reports are unblinded, unmeasured, and tangled with everything else a motivated biohacker is doing: training, sleep tracking, diet changes, and a strong expectation that an expensive injectable should do something.
Remember that even in placebo-controlled trials of the pharmaceutical version, patients on placebo often improved too. An anecdote cannot separate elamipretide from enthusiasm.
